NBTX — Nanobiotix S.A. stock price, charts and financials

Latest market price

38.89

+0.50+1.32%

Overview Short InterestFilings

NBTXQT83Nanobiotix S.A.·NASDAQ

Overview Short InterestFilings

38.89+1.32%

Loading chart...

Screen all →

ZBIO-0.99%$31.13 ADMA+3.31%$8.74 RAPP-0.46%$40.79 PVLA+1.25%$140.78 GHRS+0.43%$28.19 BHVN-0.96%$13.37 AUPH-2.08%$14.57 HRMY+1.02%$35.60

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.58	Insider Own	-	Shs Outstand	50.60M	Perf Week	-3.30%

Market Cap	1.97B	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-	Shs Float	40.68M	Perf Month	-2.76%

Enterprise Value	2.02B	PEG	-	EPS next Q	-0.36	Inst Own	-	Short Float	0.21%	Perf Quarter	10.89%

Income	-29.62M	P/S	57.77	EPS this Y	58.39%	Inst Trans	-	Short Ratio	0.99	Perf Half Y	75.38%

Sales	34.18M	P/B	-	EPS next Y	-25.38%	ROA	-35.36%	Short Interest	84.56K	Perf YTD	66.05%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	31.23%	52W High	57.88 -32.81%	Perf Year	473.84%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-74.29%	52W Low	6.17 530.38%	Perf 3Y	348.48%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	87.58% 61.54%	Gross Margin	-	Volatility	4.99% 6.15%	Perf 5Y	177.79%

Dividend TTM	-	EV/Sales	59.21	EPS Y/Y TTM	62.77%	Oper. Margin	-36.49%	ATR (14)	2.65	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.09	Sales Y/Y TTM	512.50%	Profit Margin	-80.83%	RSI (14)	49.32	Recom	2.25

Dividend Gr. 3/5Y	-	Current Ratio	1.09	EPS Q/Q	-39.38%	SMA20	-1.94%	Beta	0.78	Target Price	38.00

Payout	0.00%	Debt/Eq	-	Sales Q/Q	-91.43%	SMA50	1.03%	Rel Volume	1.33	Prev Close	38.39

Employees	100	LT Debt/Eq	-1.08	Earnings	Sep 29	SMA200	28.87%	Avg Volume	97.96K	Price	38.89

IPO Date	Dec 11, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7804.37% -87.85%	Net Debt/EBITDA	-3.53	Volume	129,986	Change	1.32%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-04-26	Reiterated	Leerink Partners	Outperform	$26 → $46
May-01-26	Reiterated	UBS	Neutral	$30
Nov-25-25	Reiterated	Leerink Partners		$14 → $26
Sep-18-25	Reiterated	Leerink Partners		$9.00 → $14
Aug-27-24	Initiated	Guggenheim	Buy	$12

Latest News

Jul-30-26

Jul-30-2604:15PM

Voting Rights and Shares Capital of the Companyglobenewswire.com

Jun-25-26

Jun-25-2605:46AM

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy PlatformSeekingAlpha

Jun-12-26

Jun-12-2604:58PM

Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A BiotechSeekingAlpha

Company

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	33	33	-8	39	5	3	3	3	4
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0	0	0
Gross Profit	33	33	-8	39	5	3	3	3	4
Selling, General and Administrative Excl. Other	23	23	22	24	19	23	17	21	15
Research and Development	26	26	44	42	34	36	28	34	25
Other Operating Expense	-3	-3	0	2	1	6	-1	0	0
Operating Income	-13	-12	-74	-29	-49	-62	-42	-52	-35
Interest Expense	12	12	9	9	6	1	0	5	1
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-3	-3	9	-5	-5	7	4	1	1
Net Income Before Taxes	-28	-27	-74	-43	-60	-56	-38	-57	-36
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-28	-27	-74	-43	-60	-56	-38	-57	-36
Net Income From Continuing Operations	-28	-27	-74	-43	-60	-56	-38	-57	-36
Net Income	-28	-27	-74	-43	-60	-56	-38	-57	-36
EPS (Recurring)	-0.58	-0.56	-1.56	-1.17	-1.72	-1.60	-1.57	-2.63	-1.79
EPS (Basic, Before Extraordinaries)	-0.58	-0.56	-1.56	-1.17	-1.72	-1.60	-1.57	-2.63	-1.79
EPS (Diluted)	-0.58	-0.56	-1.56	-1.17	-1.72	-1.60	-1.57	-2.63	-1.79
EBITDA	-14	-14	-73	-26	-46	-54	-40	-50	-35
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	56.57	33.63	-16.86	6.91	25.69	94.50	132.00	—	—
Gross Margin	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
Operating Margin	-39.39	-36.36	925.00	-74.36	-980.00	-2,066.67	-1,400.00	-1,733.33	-875.00
Net Margin	-84.85	-81.82	925.00	-110.26	-1,200.00	-1,866.67	-1,266.67	-1,900.00	-900.00
Shares Outstanding	48	48	47	37	35	35	24	22	20
Market Capitalization	1,867	1,110	135	269	128	284	396	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.